By Debra Miller, Founder and CEO of CureDuchenne I’m honored to share two transformative events that embody both the resilience of the human spirit and the strength of our community: […]
CureDuchenne is pleased to share that PTC Therapeutics has announced that the FDA has accepted for review the New Drug Application (NDA) for Translarna (ataluren) for the treatment of Duchenne […]
Read a message from our founder and CEO The recently released award-winning Netflix documentary “The Remarkable Life of Ibelin,”* highlights the life of Mats Steen, a Norwegian World of Warcraft […]
CureDuchenne Shares Updates from 29th Annual Congress of the World Muscle Society We’re at the 29th Annual Congress of the World Muscle Society this week and are pleased to share […]
CureDuchenne is pleased to communicate that Wave Life Sciences announced positive interim data from the ongoing Phase 2 FORWARD-53 study in Duchenne amenable skipping exon 53. After 24 weeks of […]
As an early investor in Dyne Therapeutics, CureDuchenne is pleased share that Dyne announced positive data from their Phase 1/2 trial of DYNE-251 in individuals with Duchenne amenable to skipping […]
World Duchenne Day 2024
NEWPORT BEACH, Calif., June 20, 2024 /PRNewswire/ — CureDuchenne, a global nonprofit committed to finding and funding a cure for Duchenne muscular dystrophy, will host webinars in English and Spanish for the Duchenne community […]
Champions Volunteer Job Board Welcome to the CureDuchenne Champions Volunteer Opportunities board! Here, you can explore a range of rewarding volunteer positions dedicated to supporting individuals and families affected by […]
